HIMS
Another day, another peptide pop
Hims & Hers stock got a fresh jolt after comments from HHS Secretary Robert F. Kennedy Jr. pointed to the FDA reconsidering restrictions on 12 peptides. The market did what the market does: it squinted at the policy change, saw “possible revenue opportunity,” and sent the shares up as much as 11% premarket.
Why investors care
If the FDA relaxes the rules, compounding pharmacies could potentially produce these peptides again. That matters because Hims has already said it wants to offer peptides if the regulatory door cracks open — and in a business like this, access is everything.
Not just a headline, but a business model nudge
This isn’t some random feel-good headline. It’s the kind of update that can change how big the addressable market looks, especially for a telehealth company trying to turn consumer demand into repeat prescriptions and sticky revenue. The stock’s nearly 14% move the day before shows traders are betting this isn’t a one-off sugar rush.
Big picture: when regulators move the goalposts, the companies waiting near the line can look like instant winners.